Back to search

University of Thessaly (UTH)

Συγκριτική Μελέτη της επίδρασης της αντιαιμοπεταλιακής αγωγής στο δείκτη τοιχωματικής κινητικότητας της αριστερής κοιλίας σε ασθενείς με οξέα ισχαιμικά σύνδρομα χωρίς ανάσπαση του ST διαστήματος

Abstract

dc:description

Within the last ten years, acute coronary syndromes have become a major health care problem with millions of patients hospitalized annually around the world. The term acute coronary syndrome (ACS) is widely used to describe any clinical presentation suggestive of acute myocardial ischemia. Faced with sush a patient, the initial priority for the clinician is to identify immediately life-threatening conditions such as myocardial infarction , aortic dissection and massive pulmonary embolism. Patients with ST- elevation myocardial infarction (STEMI) should receive, when indicated immediately reperfusion therapy. The remaining patients with an initial diagnosis of suspected ACS constitute a heterogenous group. In some, a diagnosis of acute myocardial ischemia will be confimed. They will be ultimately classified as having non -ST elevation myocardial infarction (NSTEMI), if ischemia has resulted in myocardial damage , or unstable angina (UA), if no myocardial necrosis has occured. This classification can only be made retrospectively, and because both conditions are presumed to share a common underlying pathophysiology,the term non-ST elevation acute coronary syndrome (NSTE-ACS) is commonly used and represent the 52-57 %of all acute coronary syndromes. Atherosclerosis is a chronic inflammatory disease, and atherosclerotic plague rupture bears hallmarks of a dynamic inflammatory cellular proccess. Acute atherothrombosis , thrombus formation on ruptured vulnerable atherosclerotic plaques, is at the pathological root of ACS. Although culprit lesions may not be hemodynamically flow limiting, degradation of plaque shoulder regions exposes prothrombotic matrix materials triggering local clotting cascades. In advanced or complex atheromatous lesions (Stary type IV,and V) the plaque lipid core contains apoptotic macrophage, smooth muscle cell and mesenchymall cell- debris, and free cholesterol crystals. Plague rupture exposes sudenthothelial collagen promoting platelet activation, adhension, granule release, and aggregation. The platelet surface glycoprotein (GP) IIb/IIIa changes to an active conformation, binding to activated platelets via fibrinogen bridges, and also binds platelets to subendothelial von Willebrand factor.Thromdin binds the extracellular domain of platelet - surface protease -activated receptors (PARs) initiating a signaling cascade that promotes platelet activation. Platelets change shape , expose integrins , and release a-granule contents icluding ADP, thromboxane A2, and platelet factor -4 leading to further platelel activation and aggregation and leukocyte recruiment. ADP acts as a cofactor for many platelet agonists , including thromboxane A2 (TxA2),collagen and thrombin. Platelet activation is triggered by ADP binding to G-protein coupled receptors, first the P2Y1 recepror, and then the P2Y12 receptor, with the latter receptor being the target for current thienopyridine drugs. Thienopyridines irreversibly inhibit ADP binding to the platelet surface receptor P2Y12. Previous agents , such as ticlopidine, induced adverse effects including thrombocytopenia and bone marrow failure necesitating frequent routine hematological monitoring. Glopidogrel, with a better safety profile, is the current thienopyridine of choice. Structural analysis suggests that irreversible modification of ADP -receptor site is caused by disulfide bridge formation between reactive thiol groups and a cysteine residue of the platelet ADP receptor. Blockade of platelet surface GP IIb /IIIa molecules limits platelet aggregation and also may limit the interactions between platelets, endothelium, and leukocytes.Two principal gpoups of drugs are in use currently: monoclonal antibody 7E3 , abciximab (Lilly) recognizes the active conformational state of II b/IIIa, limiting platelet -platelet binging. Small synthetic molecules, such as eptifibatide and tirofiban, are designed to competitively bind at Arg-Gly-Asp (RGD) amino acid sites, causing transient GP IIb /IIIa blockade. Eptifibatide (Integlilin) is a synthetic disulfide-linked cyclic heptapeptide modeled on the Lys - Arg- Asp sequence seen in the snake venom disintegrin from Sistrurus m barbouri (barburin). It also has a high specificity for the II b /IIIa receptor but binds the avβ3 vitronectin receptor much less avidly. We performed this study to investigate the effect of clopidogrel vs eptifibatite in regional wall motion abnoramlities and especially in wall motion score index (WMSI) in patients with non-ST elevation acute coronary syndromes.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ταρενίδης, Παναγιώτης
  • Tarenidis, Panagiotis

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/17185

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ταρενίδης, Παναγιώτης; Tarenidis, Panagiotis. Συγκριτική Μελέτη της επίδρασης της αντιαιμοπεταλιακής αγωγής στο δείκτη τοιχωματικής κινητικότητας της αριστερής κοιλίας σε ασθενείς με οξέα ισχαιμικά σύνδρομα χωρίς ανάσπαση του ST διαστήματος. University of Thessaly (UTH), 2008. http://hdl.handle.net/10442/hedi/17185